Johnson & Johnson Seeks FDA Approval for Pioneering Myasthenia Gravis Treatment
SPRING HOUSE, PA — Johnson & Johnson has taken a significant step forward in addressing generalized myasthenia gravis (gMG) by submitting a Biologics License Application to the FDA for nipocalimab. …
Johnson & Johnson Seeks FDA Approval for Pioneering Myasthenia Gravis Treatment Read More